ea0041gp151 | Pituitary - Clinical | ECE2016
Fleseriu Maria
, Melmed Shlomo
, Mangal Brian
, Strasburger Christian J
, Biermasz Nienke R
Introduction: Although biochemical markers of acromegaly disease activity, including GH and IGF1, may fluctuate from day-to-day, biochemical treatment response in clinical trials is generally monitored using single-point analyses. Accordingly, longitudinal evaluations may assess patient status more accurately. In a phase 3 trial, oral octreotide capsules (OOC) demonstrated sustained composite endpoint GH and IGF1 response for ≤13 months in 151 patients with acromegaly pr...